WST
West Pharmaceutical Services, Inc.
Set alert
- YTD
- +49.97%
- 1 year
- +48.14%
- Open
- 419.06
- Prev close
- 416.67
- Mkt cap
- 28.79B
- Vol
- 1.06M
- Avg vol
- 571.74K
- EPS
- 7.81
- P/E
- 52.83
- Div yield
- 0.25%
More statistics
- Low
- 407.67
- High
- 422.08
- Forward P/E
- 41.31
- Beta
- 0.00
- Short ratio
- 3.38
- Inst. own
- 102.49%
- Dividend
- 1.04
- Ex-div date
- Nov 9, 2026
- Earnings
- Feb 11, 2027
- 50-d avg
- 366.43
- 200-d avg
- 312.69
- 1y target
- 442.20
Key statistics
- Market cap
- 28.78B
- Enterprise value
- 28.92B
- Trailing P/E
- 52.80
- Forward P/E
- 41.31
- PEG ratio
- 3.24
- Price / sales
- 8.47
- Price / book
- 9.71
- EPS (TTM)
- 7.81
- Beta
- 0.00
- Dividend yield
- 0.25%
- Payout ratio
- 11.14%
- Profit margin
- 18.81%
- Revenue (TTM)
- 3.40B
- Revenue growth
- 8.70%
- Free cash flow
- 326.94M
- Total cash
- 464.10M
- Total debt
- 305.00M
- Return on equity
- 21.23%
- Shares outstanding
- 69.78M
- Short % of float
- 3.38%
- 50-day average
- 366.43
- 200-day average
- 312.69
Analyst view
Consensus: strong buy
- Target (low)
- 340.00
- Target (mean)
- 442.20
- Target (high)
- 500.00
- Strong buy3
- Buy12
- Hold0
- Sell0
- Strong sell1
Next earnings
Feb 11, 2027
Expected Feb 11, 2027. Consensus EPS estimate 2.27.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 11, 2027 | Dec 30, 2026 | 2.26 | — | — | — |
| Oct 29, 2026 | Sep 30, 2026 | 2.20 | 2.66 | +0.46 | +20.91% |
| Jul 23, 2026 | Jun 30, 2026 | 2.08 | 2.37 | +0.29 | +13.94% |
| Apr 23, 2026 | Mar 31, 2026 | 1.68 | 2.13 | +0.45 | +26.79% |
| Feb 12, 2026 | Dec 31, 2025 | 1.83 | 2.04 | +0.21 | +11.48% |
| Oct 23, 2025 | Sep 30, 2025 | 1.68 | 1.96 | +0.28 | +16.67% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 30, 2026 | Barclays | main | Overweight | Overweight |
| Oct 30, 2026 | Evercore ISI Group | main | Outperform | Outperform |
| Oct 13, 2026 | TD Cowen | main | Buy | Buy |
| Oct 7, 2026 | Barclays | main | Overweight | Overweight |
| Sep 22, 2026 | Morgan Stanley | up | Equal-Weight | Overweight |
| Sep 9, 2026 | UBS | main | Buy | Buy |
About West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- United States
- Website
- westpharma.com
News
- What West Pharmaceutical Services (WST) Said on Its Q3 Earnings Call
- Citigroup Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $494
- TD Cowen Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $500
- Barclays Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $500
- Evercore ISI Group Maintains Outperform on West Pharmaceutical Servs, Raises Price Target to $480
- West Pharmaceutical Services, Inc. (WST) Q3 2026 Earnings Call Transcript
- West Pharma Q3 Earnings Rise on HVP Strength, 2026 Outlook Raised
- Compared to Estimates, West Pharmaceutical (WST) Q3 Earnings: A Look at Key Metrics
- West Pharmaceutical Servs Q3 2026 Earnings Call Transcript
- West Pharmaceutical Services (WST) Q3 Earnings and Revenues Top Estimates
Your note
Sign in to keep a note on WST — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BIRKETT BERNARD JOHN | Chief Financial Officer | Conversion of Exercise of derivative security | Feb 17, 2025 | 7,520 |
| BUTHMAN MARK A | Director | Stock Award(Grant) | May 3, 2026 | 44,308 |
| FAVORITE ANNETTE F | Officer | Sale | Sep 14, 2026 | 21,817 |
| FEEHERY WILLIAM F. | Director | Stock Award(Grant) | May 3, 2026 | 32,519 |
| GREEN ERIC MARK | Chief Executive Officer | Conversion of Exercise of derivative security | Feb 17, 2026 | 175,418 |
| HOFMANN THOMAS W | Director | Stock Award(Grant) | May 5, 2025 | 44,637 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.45% | 6,651,784 | 2.74B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.56% | 4,613,134 | 1.90B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.71% | 4,015,766 | 1.66B | Jun 29, 2026 |
| FMR, LLC | 5.08% | 3,574,816 | 1.47B | Jun 29, 2026 |
| State Street Corporation | 4.76% | 3,348,698 | 1.38B | Jun 29, 2026 |
| Artisan Partners Limited Partnership | 3.43% | 2,411,792 | 994.62M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.19% | 2,242,860 | 924.96M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.60% | 1,830,358 | 754.84M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund | 2.18% | 1,530,738 | 631.28M | Jun 29, 2026 |
| Fidelity Contrafund | 1.59% | 1,120,323 | 462.02M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Growth Index Fund | 1.34% | 940,525 | 387.87M | Jun 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 937,921 | 386.80M | Sep 29, 2026 |